Skip to main content
Clinical Trials/NCT00571220
NCT00571220
Completed
Not Applicable

Mechanisms of Diabetes Control After Weight Loss Surgery

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1 site in 1 country20 target enrollmentSeptember 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gastric Bypass Surgery
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment
20
Locations
1
Primary Endpoint
Change in incretin
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Obesity and type 2 diabetes (T2DM) are increasing in the US. One third of patients seeking bariatric surgery have T2DM. Although all surgeries result in significant weight loss and often 'cure' the T2DM, the rapid onset and the magnitude of the benefits of gastric bypass (GBP) on T2DM has thus far baffled clinical scientists. Limited data suggest that the improvement in T2DM after GBP occurs very rapidly, and may not be wholly accounted for by weight loss. Secretion of incretins (gut peptides secreted in response to meals which enhance insulin secretion) is impaired in T2DM and improves after GBP, possibly due to the specific anatomical changes after this surgery. While some determinants of impaired insulin secretion, such as glucotoxicity, improve equally after diet or surgical weight loss, the improvement in the incretin effect after GBP might be specific to this surgery. The aim of this study is to determine whether the magnitude of the incretin effect on insulin secretion is greater after GBP than after an equivalent diet-induced weight loss. We will compare, in obese patients with diabetes, randomized to very low calorie diet or to GBP, the effect of an equivalent weight loss on the incretin effect (difference in insulin secretion after comparable oral and intravenous (IV) glucose loads). As more obese diabetic patients undergo GBP, understanding the mechanisms that produce improvement in their diabetes is increasingly important.

Registry
clinicaltrials.gov
Start Date
September 2005
End Date
December 2010
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • morbidly obese with type 2 diabetes candidates and being evaluated at our institution for bariatric surgery (group1); morbidly obese patients with type 2 diabetes who want to lose weight by diet.

Exclusion Criteria

  • any condition that would be contra-indicated for bariatric surgery (ex:unstable angina)
  • diabetes treated by insulin, thiazolidinediones (TZD), exenatide, DPP-IV inhibitors
  • HbA1C \> 8%

Outcomes

Primary Outcomes

Change in incretin

Time Frame: One month

Change in incretin (gastric inhibitory peptide \[GIP\] and glucagon-like peptide-1 \[GLP-1\])

Study Sites (1)

Loading locations...

Similar Trials